XPeng Faces Headwinds as Major Hedge Fund Exits Entire Stake Texas Instruments TXN Draws Analyst Scrutiny Amid Semiconductor Cycle Shifts Asia Pacific Office Investment Surges 20 in Early FY26 as Prime Sector Leads Arabica Coffee Prices Surge to Record High After USColombia Tariff Tensions Ease Deere Company Reports Fiscal Second Quarter 2026 Results China Urges APEC Cooperation as Commerce Minister Skips Meeting Over Urgent Official Business LOCO Q1 2026 Earnings Strong EPS Beat Highlights Operational Resilience in Challenging Environment First Merchants Corporation Depository Shares FRMEP Q1 2026 Earnings EPS Beats Estimates by 895 Amid Stable Market Conditions NEWTI Q1 2026 Earnings EPS Misses Estimates Revenue Not Disclosed Absci Corporation Q1 2026 Earnings Surprise EPS Beat Amid No Revenue Disclosure SEGG Q1 2025 Earnings Negative EPS Reported Amid Revenue Uncertainty Stock Declines Enpro Inc NPO Q1 2026 Earnings Slight EPS Beat as Stock Gains on Operational Discipline Proficient Auto Logistics PAL Gains 276 as Buyers Defend Support at 495 NSTS Bancorp Inc NSTS Holds Steady at 1377 as Traders Eye Support and Resistance Levels NeoConcept International NCI Edges Lower by 032 Holding Near Support as Consolidation Persists Enovis Corporation ENOV Holds Near Support Amid Modest Decline US Physical Therapy USPH Slips Slightly as Stock Consolidates Near Key Support PharmaCyte Biotech PMCB Q1 2026 Earnings Narrowing Loss Amid Strategic Pipeline Progress AI Q1 2026 Earnings EPS Misses Estimates as Subscription Momentum Drives Stock Higher VSE Corporation Tangible Equity Units VSECU Q1 2026 Earnings Strong Earnings Beat Amid Modest Stock Decline MIDD Q1 2026 Earnings EPS Surpasses Estimates by 915 Driving Positive Market Reaction VIR Q1 2026 Earnings Significant EPS Miss Despite Minimal Revenue FLY Q1 2026 Earnings EPS Beat Offset by Lack of Revenue Stock Surges Fraudulent Art Scheme Targeting Sothebys Underscores Auction House Due Diligence Risks CVNA Q1 2026 Earnings EPS Surpasses Estimates Despite Revenue Uncertainty Cyclerion Therapeutics CYCN Edges Higher as Shares Test Key Resistance Levels